Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX), Omega Therapeutics (OMGA) and Karuna Therapeutics (KRTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX – Research Report), Omega Therapeutics (OMGA – Research Report) and Karuna Therapeutics (KRTX – Research Report).

Neurocrine (NBIX)

Piper Sandler analyst David Amsellem reiterated a Hold rating on Neurocrine today and set a price target of $100.00. The company’s shares closed last Tuesday at $110.94.

According to TipRanks.com, Amsellem has 0 stars on 0-5 stars ranking scale with an average return of -6.8% and a 37.6% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Harmony Biosciences Holdings, and Amphastar Pharmaceuticals.

Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $133.37, which is a 25.3% upside from current levels. In a report released yesterday, RBC Capital also assigned a Hold rating to the stock with a $128.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Omega Therapeutics (OMGA)

Omega Therapeutics received a Buy rating and a $10.00 price target from Piper Sandler analyst Edward Tenthoff today. The company’s shares closed last Tuesday at $1.37.

According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 3.9% and a 34.2% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Milestone Pharmaceuticals, and Arvinas Holding Company.

Omega Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.80.

Karuna Therapeutics (KRTX)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karuna Therapeutics today and set a price target of $235.00. The company’s shares closed last Tuesday at $166.61, close to its 52-week low of $158.38.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 3.4% and a 42.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Intra-Cellular Therapies, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karuna Therapeutics with a $268.42 average price target, representing a 65.6% upside. In a report issued on October 17, Leerink Partners also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NBIX:

• Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
• Neurocrine Biosciences (NBIX) Q3 Earnings Cheat Sheet
• Neurocrine assumed with an Overweight at Cantor Fitzgerald
• Neurocrine price target raised to $143 from $137 at BofA
• Neurocrine price target raised to $135 from $125 at Leerink